Terrie Curran - 22 Mar 2024 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Role: President and Chief Executive, Director
Signature: Molly Henderson, Attorney-in-Fact for Terrie Curran
Issuer symbol: PHAT
Transactions as of: 22 Mar 2024
Net transactions value: -$153,513
Form type: 4
Filing time: 26 Mar 2024, 16:05:11 UTC
Previous filing: 22 Jan 2024
Next filing: 18 Jun 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PHAT	Common Stock	Sale	$153,513	-16,851	-3.9%	$9.11	410,784	22 Mar 2024	Direct	F1, F2
holding	PHAT	Common Stock						3,840	22 Mar 2024	By 401(k)

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.11 to $9.28. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2	Includes 1,604 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2024.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.11 to $9.28. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Includes 1,604 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2024.